2017 Fiscal Year Final Research Report
Post-GWAS study for identification of druggable target of AF
| Project/Area Number |
26293052
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
笹野 哲郎 東京医科歯科大学, 大学院医歯学総合研究科, 准教授 (00466898)
井原 健介 東京医科歯科大学, 難治疾患研究所, 教授 (50770210)
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Keywords | 心房細動 / ゲノムワイド関連解析 / 1塩基多型 |
|---|
| Outline of Final Research Achievements |
Genome-wide association study (GWAS) has been introduced as a tool to examine genetic risk of common diseases and to deploy personalized medicine. As a by-product of GWAS, it is also expected to identify novel pathogenic pathways and thus novel druggable targets. Atrial fibrillation (AF) is the most frequent arrhythmia and associated cerebral infarction (cardiogenic embolism) is the main cause of disability. We performed 3 GWASs for AF, and found 14 AF-sensitive single nucleotide polymorphisms (SNPs) in Japanese population. Against these 14 SNPs, we performed functional assay to identify novel druggable targets. There are SNPs associated with oxidative stress, myolysis, or differentiation of sympathetic nerve. These findings provide novel pathogenic pathways of AF, and are suggested to a potential targets of AF drugs.
|
| Free Research Field |
循環薬理学
|
